NZ Lung Cancer Research Review Issue 28

In this issue:
  -  Access to and timing of lung cancer care
  -  ACT-NOW: chemotherapy use and outcomes in NSCLC
  -  Lung cancer screening in routine practice
  -  Cancer risk after smoking cessation
  -  Link between CVD and lung cancer
  -  Brigatinib vs alectinib in ALK-positive NSCLC
  -  Selpercatinib in RET fusion-positive NSCLC
  -  Osimertinib ± chemotherapy in EGFR-mutated NSCLC
  -  Neoadjuvant immunotherapy in NSCLC 

Please login below to download this issue (PDF)